Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 22;21(1):275.
doi: 10.1186/s12967-023-04117-3.

The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022

Paolo A Ascierto  1 , Renier Brentjens  2 , Samir N Khleif  3 , Kunle Odunsi  4 , Katayoun Rezvani  5 , Marco Ruella  6 , Ryan J Sullivan  7 , Bernard A Fox  8 , Igor Puzanov  2
Affiliations

The "Great Debate" at Immunotherapy Bridge 2022, Naples, November 30th-December 1st, 2022

Paolo A Ascierto et al. J Transl Med. .

Abstract

The 2022 Immunotherapy Bridge congress (November 30-December 1, Naples, Italy) featured a Great Debate session which addressed three contemporary topics in the field of immunotherapy. The debates included counterpoint views from leading experts and considered whether adoptive cell therapy (ACT) has a role in the treatment of solid tumors, the use of peripheral/blood biomarkers versus tumor microenvironment biomarkers for cancer immunotherapy and the role of chimeric antigen receptor T cell versus natural killer cell therapy. As is the tradition in the Immunotherapy Bridge Great Debates, speakers are invited by the meeting Chairs to express one side of the assigned debate and the opinions given may not fully reflect their own personal views. Audiences voted in favour of either side of the topic both before and after each debate.

Keywords: Adoptive cell therapy; Biomarkers; CAR therapy; Cancer; Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Paolo A. Ascierto (PAA): Employment or Leadership Position: None; Consultant/Advisory Role: Bristol-Meyers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, AstraZeneca, Sun Pharma, Sanofi, Idera, Sandoz, Immunocore, 4SC, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, OncoSec, Nouscom, Lunaphore, Seagen, iTeos, Medicenna; Stock Ownership: None; Research Funding: Bristol-Meyers Squibb, Roche-Genentech, Pfizer, Sanofi; Expert Testimony: None; Other Remuneration: None. Renier Brentjens (RB): in the past 2 (two) years he has received the funding listed below from the following sources: Consultancy, Patents & Royalties, Research Funding—BMS; Patents & Royalties—Caribou; Consultancy, Ended employment in the past 24 months—Gracell Biotechnologies, Inc.; Patents & Royalties—Sanofi; Consultant—Atara Biotherapeutics Inc.; Consultant, Scientific Advisory Board member—CoImmune; Consultant, Scientific Advisory Board member—Triumvira. Samir N. Khleif (SNK): Owner/Founder: Georgiamune, LLC; Board Member: Advaxis Board of Directors; Consultant/Advisory Board: aMoon, Adaptive Biotechnology, AstraZeneca, Aummune, Bioline Therapeutics, Coherus, GI Innovation, Incyte, IO Biotechnology, Israel Biotech Fund GP Partners, KAHR Medical, Lycera, McKinsey Health, Merck, Nectin TX, Northwest Biotherapeutics, RAPA Therapeutics, Syndax, Tessa Therapeutics, UbiVac; Research Support: AstraZeneca, BioLine Therapeutics, Bristol-Myers Squibb, HeatBio, IO Biotechnologies, KAHR Medical, Lycera, MediImmune, Merck, Pelican Therapeutics, Syndax; Stock: Advaxis Immunotherapy, Princeton, NJ; Northwest Biotherapeutics, Bethesda, MD; PDS Biotechnology, North Brunswick Township, NJ; IO Biotechnology, Copenhagen; KAHR Medical, Israel; 2022 Speaker Honoraria: AstraZeneca; Memberships: AACR, ASCO, NCPF, NRG, PICI, SITC, TCL—Tomouh Community of Leaders; Editorial Advisory: Omniscient, pte; Springer. Kunle Odunsi (KO): he has received the funding from: AstraZeneca and Tesaro. Scientific Advisory Boards: Daiichi-Sanyo. Co-founder: Tactiva Therapeutics. Katy Rezvani (KR): License agreement and research agreement: Takeda—to develop CB-CAR NK cells for the treatment of B-cell malignancies and other cancers, which creates an institutional conflict of interest under MD Anderson policy; Affimed. Educational grant: Pharmacyclics; SAB: AvengeBio, Bayer, Caribou Biosciences, GemoAb, GSK, Navan Technologies, and Virogin Biotech. Marco Ruella (MR): he has received the funding listed below from the following sources: Inventor: CART technologies, Univ. of Pennsylvania, partly licensed to Novartis, Tmunity, and viTToria biotherapeutics; Research Funding: AbClon, Beckman-Coulter, Lumicks, ONI, Orflo; Consultancy/Honoraria: nanoString, GLG, Bayer, Sana, BMS, GSK; Advisory Board: AbClon, viTToria bio, Scailyte; Scientific Founder: viTToria biotherapeutics. Ryan J. Sullivan (RJS): he has received the funding listed below from the following sources: Merck; Novartis; Pfizer; BMS. Bernard A. Fox (BAF): Scientific Advisory Board (Advising/Consulting): Akoya/PerkinElmer, AstraZeneca/Definiens, Bristol-Myers Squibb, CanWell, Hookipa, Incyte, Macrogenics, NeoGenomics, PrimeVax (BOD, stock), Turnstone, UbiVac, Co-founder/CEO/stock, Ultivue; Research Support: Akoya/PerkinElmer, Bristol-Myers Squibb, Definies/AstraZeneca, Incyte, Macrogenics, NanoString, OncoSec Shimadzu, Viralytics/Merck. Igor Puzanov (IP): Consulting/Honoraria: Nektar, Amgen, Roche, Oncorus; Advisory Board: Bristol-Myers Squibb, Regeneron, Nouscom, Nektar; Institutional Clinical Trial Support: Nektar, Idera, Oncosec, Amgen, Immunocore, Dynavax, Rubius, SQZ, ADC; DSMC: Nouscom.

Figures

Fig. 1
Fig. 1
Cell therapy for solid tumor: yes or no? Audience response before and after debate
Fig. 2
Fig. 2
Peripheral/blood biomarkers versus TME biomarkers. Audience response before and after debate
Fig. 3
Fig. 3
CAR T cell therapy versus CAR natural killer cell therapy. Audience response before and after debate
See this image and copyright information in PMC

References

    1. de Fernández Larrea C, Staehr M, Lopez AV, Ng KY, Chen Y, Godfrey WD, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 2020;1(2):146–154. doi: 10.1158/2643-3230.BCD-20-0020. - DOI - PMC - PubMed
    1. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049–1058. doi: 10.1038/s41587-019-0192-1. - DOI - PubMed
    1. Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M, Brentjens RJ. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133–4141. doi: 10.1182/blood-2011-12-400044. - DOI - PMC - PubMed
    1. Yeku OO, Purdon TJ, Koneru M, Spriggs D, Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017;7(1):10541. doi: 10.1038/s41598-017-10940-8. - DOI - PMC - PubMed
    1. Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, et al. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep. 2018;23(7):2130–2141. doi: 10.1016/j.celrep.2018.04.051. - DOI - PMC - PubMed

Substances